Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Alnylam Pharmaceuticals, Inc.    ALNY

ALNYLAM PHARMACEUTICALS, INC.

(ALNY)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector news

Alnylam: 2Q Earnings Snapshot

share with twitter share with LinkedIn share with facebook
08/06/2020 | 11:19am EDT

CAMBRIDGE, Mass. (AP) _ Alnylam Pharmaceuticals Inc. (ALNY) on Thursday reported a loss of $179.2 million in its second quarter.

The Cambridge, Massachusetts-based company said it had a loss of $1.56 per share.

The results beat Wall Street expectations. The average estimate of seven analysts surveyed by Zacks Investment Research was for a loss of $1.79 per share.

The RNA interference drug developer posted revenue of $104 million in the period, which also beat Street forecasts. Six analysts surveyed by Zacks expected $98.7 million.

Alnylam shares have increased 27% since the beginning of the year. The stock has more than doubled in the last 12 months.

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on ALNY at https://www.zacks.com/ap/ALNY

Automated Insights, source Associated Press News


share with twitter share with LinkedIn share with facebook
All news about ALNYLAM PHARMACEUTICALS, INC.
10/30ALNYLAM PHARMACEUTICALS : Named a Top Biopharma Employer by Science Magazine
AQ
10/30ALNYLAM PHARMACEUTICALS : Wins Prestigious Prix Galien Award for Best Biotechnol..
BU
10/29ALNYLAM PHARMACEUTICALS : Named a Top Biopharma Employer by Science Magazine
BU
10/23ALNYLAM PHARMACEUTICALS : to Webcast Conference Call Discussing Third Quarter 20..
AQ
10/23ALNYLAM PHARMACEUTICALS : Presents Positive Results from ILLUMINATE-B Phase 3 st..
AQ
10/22ALNYLAM PHARMACEUTICALS : to Webcast Conference Call Discussing Third Quarter 20..
BU
10/22ALNYLAM PHARMACEUTICALS : Presents Positive Results from ILLUMINATE-B Phase 3 St..
BU
10/19ALNYLAM PHARMACEUTICALS : Receives Positive CHMP Opinion for OXLUMO for the Trea..
AQ
10/16ALNYLAM PHARMACEUTICALS : Receives Positive CHMP Opinion for OXLUMO™ (luma..
BU
10/14VIR BIOTECHNOLOGY : and Alnylam to Webcast tual Fireside Chat at H.C. Wainwright..
AQ
More news
Financials (USD)
Sales 2020 467 M - -
Net income 2020 -711 M - -
Net cash 2020 1 265 M - -
P/E ratio 2020 -19,9x
Yield 2020 -
Capitalization 14 261 M 14 261 M -
EV / Sales 2020 27,8x
EV / Sales 2021 15,9x
Nbr of Employees 1 323
Free-Float 99,2%
Chart ALNYLAM PHARMACEUTICALS, INC.
Duration : Period :
Alnylam Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ALNYLAM PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 24
Average target price 163,17 $
Last Close Price 122,97 $
Spread / Highest target 83,0%
Spread / Average Target 32,7%
Spread / Lowest Target -26,8%
EPS Revisions
Managers
NameTitle
John M. Maraganore Chief Executive Officer & Director
Yvonne L. Greenstreet President & Chief Operating Officer
Michael W. Bonney Chairman
Jeffrey Poulton Chief Financial & Accounting Officer
Akshay K. Vaishnaw President-Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
ALNYLAM PHARMACEUTICALS, INC.6.77%14 261
LONZA GROUP AG57.19%45 022
IQVIA HOLDINGS INC.-0.34%29 650
SEAGEN INC.45.98%29 023
CELLTRION, INC.33.15%28 374
MODERNA, INC.244.94%26 623